ENTA News and Press, Enanta Pharmaceuticals Inc. From 02/20/20

In my previous article regarding NASH disease and the potential winners of the first wave drugs, I made a comparison of efficacy of the late stage drug candidates which have better chances to be first in the market of NASH. For those who are interested, please click here . In this article, ...

Enanta Pharmaceuticals, Inc. (ENTA) Q1 2020 Results Conference Call February 06, 2020 04:30 PM ET Company Participants Carol Miceli - Director, IR Dr. Jay Luly - President and CEO Paul Mellett - CFO Nathalie Adda - SVP and CMO Conference Call Participants Brian Abrahams -...

Image source: The Motley Fool. Enanta Pharmaceuticals Inc   (NASDAQ: ENTA) Q1 2020 Earnings Call Feb 6, 2020 , 4:30 p.m. ET Operator Continue reading

Enanta Pharma (NASDAQ: ENTA ): Q1 GAAP EPS of $0.65 beats by $0.09 . More news on: Enanta Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Webcast and Conference Call Today at 4:30 p.m. ET Positive results from part 1 of the Phase 1a/b clinical study of EDP-514 in healthy subjects - Part 2 initiated in nuc-suppressed chronic hepatitis B virus patients Research and development programs progressing well -- several...

Enanta Pharma (NASDAQ: ENTA ) is scheduled to announce Q1 earnings results on Thursday, February 6th, after market close. The consensus EPS Estimate is $0.60 (-52.0% Y/Y) and the consensus Revenue Estimate is $58.75M (-15.9% Y/Y). Over the last 2 years, ENTA  has beaten EPS estima...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating and developing small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2...

The following slide deck was published by Enanta Pharmaceuticals, Inc. in conjunction with this Read more ...

Enanta Pharmaceuticals (NASDAQ: ENTA ) will provide an update on its R&D programs, introduce its newest program in human metapneumovirus (hMPV), as well as provide an update on its business outlook for 2020, during its presentation at the 38 th Annual J.P. Morgan Healthcare Confe...

Presentation and Q&A breakout to be webcast on January 13, 2020 beginning at 2:30 p.m. Pacific Time Several clinical milestones expected in RSV, HBV, and NASH/PBC programs in 2020 New discovery program in human metapneumovirus (hMPV) Strong balance sheet and royalty ...